This is the authors' abstract. We don't add key points for this paper.
Current treatment options for treatment-resistant depression have considerable limitations in terms of efficacy and patient acceptability. Esketamine is expected to address an unmet medical need in this population through its novel mechanism of action and rapid onset of antidepressant efficacy. The study supports the efficacy and safety of esketamine nasal spray as a rapidly acting antidepressant for patients with treatment-resistant depression.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Popova et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: